Compared with nonusers, DPP-4 inhibitor users were associated with a lower risk of PAD (HR 0.84; 95% CI 0.80–0.88) and lower-extremity amputation (HR 0.65; 95% CI 0.54–0.79) [97]. The gene discussed is DPP4; the disease is peripheral arterial disease.